Regeneron (REGN)
AI-powered earnings call analysis for Regeneron. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.
Subscribe
Subscribe
Get Episode Notifications
Get an email when new Regeneron earnings episodes are released.
Next Episode
Regeneron earnings call scheduled for Jan 28, 2027 (before market open)
New episode expected Jan 29, 2027
Latest Episode
Q3 2026 Earnings
7:27 • 10/30/2026
All Episodes
Q3 2026 Earnings
7:27Q3 revenue reached $5.1B (+36%) with EPS growth of 70%, driven by record sales of Dupixent, EYLEA HD, and Libtayo; $1B Sanofi deal expanded alliance for 4 next-gen antibodies.
Q2 2026 Earnings
6:52Regeneron Q2 2026: $4.3B revenue (+17%), Dupixent $6B (+38%), EYLEA HD $596M (+52%), Libtayo $489M (+29%); $3.1B Sanofi balance repaid; 50 clinical programs with cemdisiran FDA decision November.
Q1 2026 Earnings
7:17Regeneron delivered 19% revenue growth to $3.6B in Q1 2026 driven by DUPIXENT's 31% expansion and EYLEA HD's 52% surge, while advancing late-stage pipeline programs including cemdisiran for myasthenia gravis with superior efficacy data.
Q4 2025 Earnings
7:56AI-generated analysis of REGN's Q4 2025 earnings call.
